Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06522997 · ClinicalTrials.gov registry record · Phase 2

A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

A Phase 2 study of Chronic Kidney Disease, sponsored by Bayer.

Active
Registry status
Phase 2
Development phase
700
Enrollment target
20
Study locations

NCT06522997 is a Phase 2 study of Chronic Kidney Disease that is active but no longer recruiting, run by Bayer. The registered enrollment target is 700 participants, below the 3,200-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06522997, a Phase 2 study of Chronic Kidney Disease, is active but no longer recruiting, sponsored by Bayer.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
700 participants
Enrollment target
20
Study locations

Study Summary

Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), CKD is a condition in which the kidneys' ability to work properly gradually decreases over time. A common sign of decreasing kidney function is the body losing too much of a protein called albumin in the urine. This condition is known as albuminuria. This can lead to a faster decline in kidney function. People who have high blood pressure and diabetes are more likely to have CKD and are at a higher risk of complications related to it. BAY3283142 is a new drug that is being developed to treat people with CKD. It works by activating a protein that helps relax blood vessels and is thought to have beneficial effects in CKD. In this study, researchers want to learn about how well different doses of BAY3283142 work when taken with standard treatment for CKD in reducing albumin in the urine of participants with CKD. They will compare the results of the change in the urine albumin-creatinine ratio (UACR) after 16 weeks for BAY3283142 with a placebo. A placebo looks like the study drug but does not have any medicine in it. During the study, participants will take either of the following drugs: * BAY3283142: Participants will take BAY3283142 as tablets by mouth. * Placebo: Participants will take it in the same way as BAY3283142. Participants will continue taking the available standard treatment for CKD and other conditions they may have (for example, heart conditions and diabetes). At the start of this study, the researchers will check the medical history and current medications of the participants. They will also perform a complete health check-up of all the participants. Researchers will take urine and blood samples from the participants at different time points to measure UACR and eGFR. Participants will be divided equally into different groups. Only 1 group will receive placebo and the other groups will receive BAY3283142. Participants will take their assigned treatment f

Conditions Studied

Chronic Kidney Disease

Interventions

  • DRUG Placebo
  • DRUG BAY3283142

Study Locations (20)

Florida

  • Nova Clinical Research - Blake Medical Center - Bradenton
  • Renstar Medical Research - Deerwood Clinic - Ocala
  • Elixia Central Florida - Orlando
  • Florida Institue for Clinical Research - Orlando

California

  • Balboa Research SMO+ - Chula Vista - West - Chula Vista
  • Balboa Research SMO+ - La Mesa - La Mesa
  • California Kidney Specialists - San Dimas - San Dimas

North Carolina

  • Triad Internal Medicine - Asheboro - Asheboro
  • Eastern Nephrology Associates - New Bern - New Bern
  • Brookview Hills Research Associates, LLC - Winston-Salem

Texas

  • Renal Disease Research Institute | Landry - Dallas
  • Southwest Houston Research, Ltd. - Houston
  • Clinical Advancement Center, PLLC - San Antonio

Illinois

  • Research by Design, LLC | Chicago, IL - Chicago
  • Nephrology Associates of Northern Illinois and Indiana - Hinsdale - Hinsdale

Tennessee

  • Knoxville Kidney Center, PLLC - Knoxville
  • Vanderbilt University Medical Center - Nashville

Alabama

  • Nephrology Consultants, LLC - Huntsville

Connecticut

  • Yale University School of Medicine - New Haven

Trial Details

FieldValue
Enrollment Target 700 participants
Start Date 2024-08-08
Est. Completion 2026-03-17
Phase Phase 2

Sponsor

Bayer

591 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06522997

The ClinicalTrials.gov registry entry for NCT06522997 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,200-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (78% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06522997 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06522997 about?

NCT06522997 is a clinical study titled "A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease". Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), CKD is a condition in which the kidneys' ability to work properly gradually decreases over time. A common sign of decreasing kidney function is the body losing too much of a protein called albumin in the ...

What is the current status of trial NCT06522997?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 700 participants. The study started on 2024-08-08. Estimated completion is 2026-03-17.

What conditions does trial NCT06522997 study?

This clinical trial studies the following conditions: Chronic Kidney Disease.

What interventions are being tested in trial NCT06522997?

The interventions under investigation include: Placebo (DRUG), BAY3283142 (DRUG).

Who is sponsoring clinical trial NCT06522997?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06522997 being conducted?

This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Kidney Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.